Function of the Retinal Pigment Epithelium in Patients With Neurofibromatosis Type 1

Romain Touzé, Marc M Abitbol, Dominique Bremond-Gignac, Matthieu P Robert, Romain Touzé, Marc M Abitbol, Dominique Bremond-Gignac, Matthieu P Robert

Abstract

Purpose: Retinal and choroidal abnormalities in neurofibromatosis type 1 (NF1) remain poorly studied. It has been reported, however, that the function of the retinal pigment epithelium (RPE) in NF1 was abnormal, with a supra-normal Arden ratio of the electro-oculogram (EOG). This study aims to evaluate the function of the RPE, using EOG, first in patients with NF1 compared to controls and second in patients with NF1 with choroidal abnormalities compared to patients with NF1 without choroidal abnormalities.

Methods: This prospective case-control study included 20 patients with NF1 (10 patients with choroidal abnormalities and 10 patients without) and 10 healthy patients, matched for age. A complete ophthalmologic assessment with multimodal imaging, an EOG, and a full-field electroretinogram were performed for each included patient. The main outcome measured was the EOG light peak (LP)/dark trough (DT) ratio.

Results: The LP/DT ratio was 3.02 ± 0.52 in patients with NF1 and 2.63 ± 0.31 in controls (P = 0.02). DT values were significantly lower in patients with NF1 than in controls (240 vs. 325 µV, P = 0.02), while light peak values were not significantly different (P = 0.26). No difference was found for peak latencies. No significant correlation between the surface and number of choroidal abnormalities and EOG parameters was demonstrated.

Conclusions: This study confirms the dysfunction of the RPE in patients with NF1, involving a lower DT and a corresponding higher LP/DT ratio. We hypothesize that this pattern may be due to a dysregulation of the melanocytogenesis, inducing a disruption in Ca2+ ion flux and an abnormal polarization of the RPE.

Conflict of interest statement

Disclosure: R. Touzé, None; M.M. Abitbol, None; D. Bremond-Gignac, None; M.P. Robert, None

Figures

Figure 1.
Figure 1.
Typical supra-normal EOG results obtained in a child with NF1 (A) and a control (B). In the child with NF1, the dark trough occurred at 9 minutes with values of 163 µV for the right eye and 144 µV for the left eye, and the light peak occurred at 23 to 24 minutes with values of 611 µV for the right eye and 654 µV for the left eye with an LP/DT ratio of 3.74 and 4.54, respectively. In the healthy child, the dark trough occurred at 12 minutes with values of 260 µV for the right eye and 328 µV for the left eye, and the light peak occurred at 23 to 24 minutes with values of 746 µV for the right eye and 856 µV for the left eye with an LP/DT ratio of 2.87 and 2.61, respectively. OD, oeil droit meaning right eye; OG, oeil gauche meaning left eye.
Figure 2.
Figure 2.
Boxplot of electro-oculogram values obtained between patients with NF1 and controls. Each value, including LP, DT, and LP/DT ratio, is represented. The first quartile is the bottom of the box and the third quartile the top of the box. The center line represents the median value; whiskers include the 5th to 95th percentiles of data; outliers are represented as black dots. P values are indicated above.
Figure 3.
Figure 3.
Near-infrared imaging fundus in a 12-year-old boy with NF1: (A) right eye and (B) left eye. Typical patchy bright lesions were observed in both eyes, representing typical choroidal abnormalities (white arrow). Area of these abnormalities was 12.18 mm² on the right eye and 11.36 mm² on the left eye. Normal near-infrared imaging fundus in a healthy 11-year-old girl is presented for comparison: (C) right eye and (D) left eye.
Figure 4.
Figure 4.
Comparative spectral-domain optical coherence tomography scans with EDI in children with NF1 and choroidal abnormalities (A), without choroidal abnormalities (B), and without NF1 (C). The subfoveal choroidal thickness was assessed in each patient in a single point located behind the fovea (black arrow). These scans compared choroidal thickness of a choroidal abnormality (red arrow, A) and correspondent area in a patient with NF1 but without a choroidal abnormality (red arrow, B) and control (red arrow, C). The opposite choroidal thickness, 2000 µm from the fovea temporally, was measured (white arrow). No statistical difference of choroidal thickness was observed between groups.

References

    1. Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ.. Neurofibromatosis type 1. Nat Rev Dis Primer. 2017; 3(1): 17004.
    1. Uusitalo E, Leppävirta J, Koffert A, et al. .. Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol. 2015; 135(3): 904–906.
    1. Wallace MR, Marchuk DA, Andersen LB, et al. .. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990; 249(4965): 181–186.
    1. Neurofibromatosis. Conference statement. National Institutes of Health consensus development. Arch Neurol. 1988; 45: 575–578.
    1. Legius E, Messiaen L, Wolkenstein P, et al. .. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021; 23(8): 1506–1513.
    1. Listernick R, Charrow J, Greenwald M, Mets M.. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr. 1994; 125(1): 63–66.
    1. Yasunari T, Shiraki K, Hattori H, Miki T.. Frequency of choroidal abnormalities in neurofibromatosis type 1. Lancet. 2000; 356(9234): 988–992.
    1. Viola F, Villani E, Natacci F, et al. .. Choroidal abnormalities detected by near-infrared reflectance imaging as a new diagnostic criterion for neurofibromatosis 1. Ophthalmology. 2012; 119(2): 369–375.
    1. Nakakura S, Shiraki K, Yasunari T, Hayashi Y, Ataka S, Kohno T.. Quantification and anatomic distribution of choroidal abnormalities in patients with type I neurofibromatosis. Graefes Arch Clin Exp Ophthalmol. 2005; 243(10): 980–984.
    1. Parrozzani R, Clementi M, Frizziero L, et al. .. In vivo detection of choroidal abnormalities related to NF1: feasibility and comparison with standard NIH diagnostic criteria in pediatric patients. Invest Ophthalmol Vis Sci. 2015; 56(10): 6036–6042.
    1. Vagge A, Camicione P, Capris C, et al. .. Choroidal abnormalities in neurofibromatosis type 1 detected by near-infrared reflectance imaging in paediatric population. Acta Ophthalmol (Copenh). 2015; 93(8): e667–e671.
    1. Moramarco A, Giustini S, Nofroni I, et al. .. Near-infrared imaging: an in vivo, non-invasive diagnostic tool in neurofibromatosis type 1. Graefes Arch Clin Exp Ophthalmol. 2018; 256(2): 307–311.
    1. Rao RC, Choudhry N.. Enhanced depth imaging spectral-domain optical coherence tomography findings in choroidal neurofibromatosis. Ophthalmic Surg Lasers Imaging Retina. 2014; 45(5): 466–468.
    1. Kumar V, Singh S.. Multimodal imaging of choroidal nodules in neurofibromatosis type-1. Indian J Ophthalmol. 2018; 66(4): 586–588.
    1. Wolter JR. Nerve fibrils in ovoid bodies: with neurofibromatosis of the choroid. Arch Ophthalmol. 1965; 73(5): 696–699.
    1. Ueda-Consolvo T, Miyakoshi A, Ozaki H, Houki S, Hayashi A.. Near-infrared fundus autofluorescence-visualized melanin in the choroidal abnormalities of neurofibromatosis type 1. Clin Ophthalmol. 2012; 6: 1191–1194.
    1. Lubiński W, Zajaczek S, Sych Z, Penkala K, Palacz O, Lubiński J.. Electro-oculogram in patients with neurofibromatosis type 1. Doc Ophthalmol Adv Ophthalmol. 2001; 103(2): 91–103.
    1. Lubiński W, Zajączek S, Sych Z, Penkala K, Palacz O, Lubiński J.. Supernormal electro-oculograms in patients with neurofibromatosis type 1. Hered Cancer Clin Pract. 2004; 2(4): 193–196.
    1. Touzé R, Manassero A, Bremond-Gignac D, Robert MP.. Long-term follow-up of choroidal abnormalities in children with neurofibromatosis type 1. Clin Experiment Ophthalmol. 2021; 49(5): 516–519.
    1. Constable PA, Bach M, Frishman LJ, Jeffrey BG, Robson AG.. ISCEV standard for clinical electro-oculography (2017 update). Doc Ophthalmol Adv Ophthalmol. 2017; 134(1): 1–9.
    1. McCulloch DL, Marmor MF, Brigell MG, et al. .. ISCEV standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol. 2015; 130(1): 1–12.
    1. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev. 2005; 85(3): 845–881.
    1. Sparrow JR, Hicks D, Hamel CP.. The retinal pigment epithelium in health and disease. Curr Mol Med. 2010; 10(9): 802–823.
    1. Schraermeyer U, Heimann K.. Current understanding on the role of retinal pigment epithelium and its pigmentation. Pigment Cell Res. 1999; 12(4): 219–236.
    1. Wiriyasermkul P, Moriyama S, Nagamori S.. Membrane transport proteins in melanosomes: regulation of ions for pigmentation. Biochim Biophys Acta Biomembr. 2020; 1862(12): 183318.
    1. Panessa BJ, Zadunaisky JA.. Pigment granules: a calcium reservoir in the vertebrate eye. Exp Eye Res. 1981; 32(5): 593–604.
    1. Salceda R, Sánchez-Chávez G.. Calcium uptake, release and ryanodine binding in melanosomes from retinal pigment epithelium. Cell Calcium. 2000; 27(4): 223–229.
    1. Arun V, Worrell L, Wiley JC, Kaplan DR, Guha A.. Neurofibromin interacts with the cytoplasmic dynein heavy chain 1 in melanosomes of human melanocytes. FEBS Lett. 2013; 587(10): 1466–1473.
    1. Martuza RL, Philippe I, Fitzpatrick TB, Zwaan J, Seki Y, Lederman J. Melanin macroglobules as a cellular marker of neurofibromatosis: a quantitative study. J Invest Dermatol. 1985; 85(4): 347–350.
    1. Wolter JR, Gonzales-Sirit R, Mankin WJ.. Neurofibromatosis of the choroid. Am J Ophthalmol. 1962; 54(2): 217–225.
    1. Cordes M, Bucichowski P, Alfaar AS, et al. .. Inhibition of Ca2+ channel surface expression by mutant bestrophin-1 in RPE cells. FASEB J. 2020; 34(3): 4055–4071.
    1. Gahlot DK, Hansen E.. Electro-oculography in albinos. Acta Ophthalmol (Copenh). 1974; 52(2): 220–224.
    1. Reeser F, Weinstein GW, Feiock KB, Oser RS.. Electro-oculography as a test of retinal function. Am J Ophthalmol. 1970; 70(4): 505–514.
    1. Nusinowitz S, Sarraf D.. Retinal function in X-linked ocular albinism (OA1). Curr Eye Res. 2008; 33(9): 789–803.
    1. McKay BS. Pigmentation and vision: is GPR143 in control? J Neurosci Res. 2019; 97(1): 77–87.
    1. Cortese K, Giordano F, Surace EM, et al. .. The ocular albinism type 1 (OA1) gene controls melanosome maturation and size. Invest Opthalmol Vis Sci. 2005; 46(12): 4358.
    1. Grønskov K, Ek J, Brondum-Nielsen K.. Oculocutaneous albinism. Orphanet J Rare Dis. 2007; 2(1): 43.
    1. Garner A, Jay BS.. Macromelanosomes in X-linked ocular albinism. Histopathology. 1980; 4(3): 243–254.
    1. Thavikulwat AT, Lopez P, Caruso RC, Jeffrey BG.. The effects of gender and age on the range of the normal human electro-oculogram. Doc Ophthalmol Adv Ophthalmol. 2015; 131(3): 177–188.
    1. Nagra M, Gilmartin B, Thai NJ, Logan NS.. Determination of retinal surface area. J Anat. 2017; 231(3): 319–324.
    1. Williams BL, Seager NA, Gardiner JD, et al. .. Chromosome 10q26–driven age-related macular degeneration is associated with reduced levels of HTRA1 in human retinal pigment epithelium. Proc Natl Acad Sci USA. 2021; 118(30): e2103617118.

Source: PubMed

3
Iratkozz fel